Literature DB >> 11993529

Cognition and health-related quality of life in a well-defined subgroup of patients with partial epilepsy.

Nadine H J Engelberts1, Martin Klein, Henk M van der Ploeg, Jan J Heimans, Herman J Adèr, Martin P J van Boxtel, Jelle Jolles, Dorotheé G A Kasteleijn-Nolst Trenité.   

Abstract

To investigate the extent and nature of the objective and subjective cognitive deficits and health-related quality of life (HRQOL) in adult outpatients with relatively well-controlled partial epilepsy without symptomatic aetiology, who were on carbamazepine (CBZ) monotherapy. Furthermore, we studied the influence of the epilepsy history and medication on various cognitive functions and the HRQOL. 56 outpatients (29 male, 27 female, mean age 41.3 years) with partial epilepsy were compared with 56 age-, gender-, and education-matched healthy controls. Patients were tested on attention, memory, speed of information processing, and executive functioning. Questionnaires aimed at measuring self-perceived cognitive functioning (CFQ) and HRQOL (SF-36) were administered. Mann Whitney-U tests were used to compare the two groups. Linear regression analysis was performed to identify the epilepsy and medication-related factors that are associated with cognitive functioning and HRQOL. Patients scored lower on measures of attention (P = 0.03), learning (P = 0.02) and speed of information processing (P = 0.00). Mental aspects of HRQOL such as fatigue were lower (P = 0.00), whereas physical functioning was unaffected. These patients also expressed reductions in mental functioning as indicated by a low self-perceived cognitive functioning (P = 0.01). Age at onset, duration of epilepsy, seizure type, seizure frequency, localisation, years on CBZ, and CBZ dosage were not related to cognitive functioning or HRQOL. Patients with partial epilepsy, even when able to maintain regular jobs, have impaired cognition and HRQOL that cannot be attributed to their epilepsy history or CBZ dosage or years of CBZ intake. Therefore, physicians should be more aware of their cognition and HRQOL, in addition to the antiepileptic drug regime.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11993529     DOI: 10.1007/s004150200008

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  6 in total

1.  It Goes Downhill From Here but Do Not Despair: Mesial Temporal Lobe Epilepsy Is a Progressive Disease, but It Can Be Benign.

Authors:  Barbara C Jobst
Journal:  Epilepsy Curr       Date:  2016 Nov-Dec       Impact factor: 7.500

2.  Cognitive outcomes in children who present with a first unprovoked seizure.

Authors:  Yoshimi Sogawa; David Masur; Christine O'Dell; Solomon L Moshe; Shlomo Shinnar
Journal:  Epilepsia       Date:  2010-09-24       Impact factor: 5.864

Review 3.  Cognitive and neurodevelopmental effects of antiepileptic drugs.

Authors:  Rebecca L Bromley; Beth A Leeman; Gus A Baker; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2011-06-17       Impact factor: 2.937

4.  Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy.

Authors:  David Victorson; Jose E Cavazos; Gregory L Holmes; Anthony T Reder; Valerie Wojna; Cindy Nowinski; Deborah Miller; Sarah Buono; Allison Mueller; Claudia Moy; David Cella
Journal:  Epilepsy Behav       Date:  2013-12-20       Impact factor: 2.937

5.  Health-related quality of life in adults with epilepsy: the effect of age, age at onset and duration of epilepsy in a multicentre Italian study.

Authors:  Valeria Edefonti; Francesca Bravi; Katherine Turner; Ettore Beghi; Maria Paola Canevini; Monica Ferraroni; Ada Piazzini
Journal:  BMC Neurol       Date:  2011-03-10       Impact factor: 2.474

6.  Health related quality of life in patients with epilepsy in Turkey.

Authors:  Fatma Karantay Mutluay; Aysegul Gunduz; Anıl Tekeoglu; Semra Oguz; Seher Naz Yeni
Journal:  J Phys Ther Sci       Date:  2016-01-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.